Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Guidelines for the automated evaluation of Elispot assays
Sylvia Janetzki, Leah Price, Hélène Schroeder, et al.
Nature Protocols (2015) Vol. 10, Iss. 7, pp. 1098-1115
Closed Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Axel Hoos
Nature Reviews Drug Discovery (2016) Vol. 15, Iss. 4, pp. 235-247
Closed Access | Times Cited: 551
The Immunoscore: Colon Cancer and Beyond
Helen K. Angell, Daniela Bruni, J. Carl Barrett, et al.
Clinical Cancer Research (2019) Vol. 26, Iss. 2, pp. 332-339
Closed Access | Times Cited: 327
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
Weijie Ma, Barbara M. Gilligan, Jianda Yuan, et al.
Journal of Hematology & Oncology (2016) Vol. 9, Iss. 1
Open Access | Times Cited: 301
Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification
Brendan Bulik‐Sullivan, Jennifer Busby, Christine D. Palmer, et al.
Nature Biotechnology (2018) Vol. 37, Iss. 1, pp. 55-63
Closed Access | Times Cited: 275
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
Kristen A. Batich, Elizabeth A. Reap, Gary E. Archer, et al.
Clinical Cancer Research (2017) Vol. 23, Iss. 8, pp. 1898-1909
Open Access | Times Cited: 254
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation
Giuseppe Masucci, Alessandra Cesano, Rachael E. Hawtin, et al.
Journal for ImmunoTherapy of Cancer (2016) Vol. 4, Iss. 1
Open Access | Times Cited: 183
Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses
Ying Kai Chan, Sean K. Wang, Colin J. Chu, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 580
Open Access | Times Cited: 152
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results
Christine D. Palmer, Amy Rappaport, Matthew J. Davis, et al.
Nature Medicine (2022) Vol. 28, Iss. 8, pp. 1619-1629
Open Access | Times Cited: 136
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results
Amy Rappaport, Chrisann Kyi, Monica Lane, et al.
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 1013-1022
Closed Access | Times Cited: 34
Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies
Yun Liu, Jianfeng Guo, Leaf Huang
Theranostics (2020) Vol. 10, Iss. 7, pp. 3099-3117
Open Access | Times Cited: 102
Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity
Stefan Kiesgen, John C. Messinger, Navin K. Chintala, et al.
Nature Protocols (2021) Vol. 16, Iss. 3, pp. 1331-1342
Open Access | Times Cited: 86
Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting
Adham S. Bear, Tatiana Blanchard, Joseph Cesare, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 83
Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection
Amy Rappaport, Sue-Jean Hong, Ciaran D. Scallan, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 42
Limited recognition of Mycobacterium tuberculosis-infected macrophages by polyclonal CD4 and CD8 T cells from the lungs of infected mice
Yash R. Patankar, Rujapak Sutiwisesak, Shayla Boyce, et al.
Mucosal Immunology (2019) Vol. 13, Iss. 1, pp. 140-148
Open Access | Times Cited: 59
2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( Part 3 –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays)
Bart Corsaro, Tong‐Yuan Yang, Rocio Murphy, et al.
Bioanalysis (2021) Vol. 13, Iss. 6, pp. 415-463
Closed Access | Times Cited: 51
Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy
Boris Gorovits, Mitra Azadeh, George Buchlis, et al.
The AAPS Journal (2023) Vol. 25, Iss. 3
Open Access | Times Cited: 20
SARS-CoV-2 specific memory T cell epitopes identified in COVID-19-recovered subjects
Juan Zhao, Ling Wang, Madison Schank, et al.
Virus Research (2021) Vol. 304, pp. 198508-198508
Open Access | Times Cited: 37
ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study
Mark N. Stein, Lawrence Fong, Ronald Tutrone, et al.
The Oncologist (2022) Vol. 27, Iss. 6, pp. 453-461
Open Access | Times Cited: 27
The Perspective of DMPK on Recombinant Adeno-Associated Virus-Based Gene Therapy: Past Learning, Current Support, and Future Contribution
Nancy Chen, Kefeng Sun, Nagendra Chemuturi, et al.
The AAPS Journal (2022) Vol. 24, Iss. 1
Open Access | Times Cited: 24
Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination
Ayman Al Jurdi, Rodrigo Benedetti Gassen, Thiago J. Borges, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 24
Differential shaping of T cell responses elicited by heterologous ChAd68/self-amplifying mRNA SIV vaccine in macaques in combination with αCTLA4, αPD-1, or FLT3R agonist
Amy Rappaport, Elena Bekerman, Gregory R. Boucher, et al.
The Journal of Immunology (2025)
Closed Access
Persistence of CMV-specific anti-HIV CAR T cells after adoptive immunotherapy
Chengxiang Wu, Nathan M. Johnson, Yu Shan, et al.
Journal of Virology (2025)
Open Access
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
Siwen Hu‐Lieskovan, Srabani Bhaumik, Kavita M. Dhodapkar, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e000705-e000705
Open Access | Times Cited: 28
Antibody Course and Memory B-Cell Response in the First Year After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Judith Kannenberg, Henning Trawinski, Reinhard Henschler, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 4, pp. 664-672
Open Access | Times Cited: 18
High-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicity
Nicolás Gonzalo Núñez, Jonas Schmid, Laura Power, et al.
Nature Immunology (2023) Vol. 24, Iss. 6, pp. 941-954
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top